Immunotherapy has revolutionized cancer treatment and substantially improved patient
outcome with regard to multiple tumour types. However, most patients still do not benefit …

Over the last decades, the growing understanding on DNA damage response (DDR)
pathways has broadened the therapeutic landscape in oncology. It is becoming increasingly …

Purpose of Review WEE1 inhibitor has been shown to potential chemotherapy or
radiotherapy sensitivity in preclinical models, particularly in p53-mutated or deficient cancer …

The replication stress response (RSR) involves a downstream kinase cascade comprising
ataxia telangiectasia-mutated (ATM), ATM and rad3-related (ATR), checkpoint kinases 1 and …

Introduction The anti-tumor activity of WEE1 inhibitors (WEE1i) in gynecological
malignancies has recently been demonstrated in clinical trials and its rationale is based on …

DNA damage repair (DDR) pathways play an essential role in maintaining genomic integrity.
DDR dysfunction leads to accumulated DNA damage, predisposition to cancer, and high …

Cancer is a systemic manifestation of aberrant cell cycle activity and dysregulated cell
growth. Genetic mutations can determine tumor onset by either augmenting cell division …

Co-stimulatory and co-inhibitory molecules play a critical role in T cell function. Tumor cells
escape immune surveillance by promoting immunosuppression. Immunotherapy targeting …

Background Adavosertib (AZD1775) is a first-in-class, selective, small-molecule inhibitor of
Wee1. Objective The safety, tolerability, pharmacokinetics, and efficacy of adavosertib …

DNA damage response inhibitors are widely used anti-cancer agents that have potent
activity against tumor cells with deficiencies in various DNA damage response proteins such …